BMRN

Q: What is the price of BioMarin Pharmaceutical (BMRN) today?

The price of BioMarin Pharmaceutical (BMRN) today is $ 58.51, with return of -17.12% compared to the last year. The price of BioMarin Pharmaceutical (BMRN) started the year trading around $ 59.43 and today it is at $ 58.51. Follow the real-time price chart, the historical price of BioMarin Pharmaceutical (BMRN) and international markets.

Q: When does BioMarin Pharmaceutical (BMRN) pay dividends?

BioMarin Pharmaceutical (BMRN) did not distribute dividends in the last year.

Q: Is BioMarin Pharmaceutical (BMRN) worth it?

Currently, BioMarin Pharmaceutical (BMRN) is priced at $ 58.51, with a P/E of 33.63%, representing a deviation of 7,676% from its historical average P/E. In the last year, the stock showed a variation of -17.12 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was -17.12%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How can I buy BioMarin Pharmaceutical (BMRN) stock?

Investing in stocks of BioMarin Pharmaceutical (BMRN) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much would 100 shares of BioMarin Pharmaceutical (BMRN) yield today?

The yield of BioMarin Pharmaceutical (BMRN) was -2.98% in the last month, -17.12% in the last year and -25.36% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.If you wanted to buy 100 stocks of BioMarin Pharmaceutical (BMRN) today, the total investment would be $ 5,851.00, based on the current price of $ 58.51.If past performance were to repeat, the return on your investment would be:In 1 year: $ 4,849.31In 5 years: $ 4,367.19In 10 years: $ 4,261.28It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

BioMarin Pharmaceutical Inc.

Price

$ 58.51

return (12m)

-17.12%

p/e

33.63

p/bv

1.93

DIVIDEND YIELD

0.00%

BMRN price

BMRN

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment BMRN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-2.98%

3 months

9.75%

1 year

-17.12%

2 years

-30.98%

5 years

-25.36%

10 years

-27.17%

Fundamentals BMRN

review the fundamentals of BioMarin Pharmaceutical shares

P/E

33.63

Sector: -3.82 Industry: -3.82

P/S (PSR)

3.64

Sector: -4.00 Industry: -4.00

P/BV

1.93

Sector: 1.96 Industry: 1.96

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

4.59%

Sector: -65.08% Industry: -65.08%

ROE

5.73%

Sector: -67.53% Industry: -67.53%

ROIC

-3.21%

Sector: -1,295.93% Industry: -1,295.93%

NET MARGIN

10.83%

Sector: -41.04% Industry: -41.04%

GROSS MARGIN

77.73%

Sector: 38.62% Industry: 38.62%

OPERATING MARGIN

12.71%

Sector: -41.08% Industry: -41.08%

EV/EBITDA

20.48

Sector: -3.78 Industry: -3.78

EV/EBIT

23.79

Sector: -3.95 Industry: -3.95

PRICE-TO-ASSETS

1.55

Sector: 1.42 Industry: 1.42

BVPS

31.70

Sector: 1.76 Industry: 1.76

EPS

1.82

Sector: -2.04 Industry: -2.04

EQUITY-TO-ASSETS RATIO

0.80

Sector: 0.40 Industry: 0.40

LIABILITIES / ASSETS

0.20

Sector: 0.40 Industry: 0.40

CAGR REVENUE 5 YEARS

11.78%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

0.00%

Sector: - Industry: -

FAIR VALUE OF BioMarin Pharmaceutical ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$ 58.51

Fair Value

$ 0.00

Upside/Downside Return potential.

-38.42%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals BMRN

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	21.49	7.27	33.81%	1.63%	$ 576.06 B	28.46%
PFE	19.79	1.65	8.35%	6.36%	$ 153.81 B	12.42%
ABBV	96.21	0.00	0.00%	2.89%	$ 406.60 B	6.91%
NVO	10.94	5.63	51.50%	4.37%	$ 171.33 B	33.05%
MRK	15.74	0.00	0.00%	2.83%	$ 287.39 B	28.08%
AZN	29.15	6.12	20.99%	1.63%	$ 298.03 B	17.41%
GILD	21.01	7.90	37.62%	2.20%	$ 178.76 B	28.90%
BMY	17.40	-3.61	-20.72%	4.13%	$ 122.75 B	14.64%
ZTS	19.90	15.97	80.25%	1.67%	$ 53.19 B	28.23%
REGN	17.37	2.50	14.41%	0.59%	$ 78.27 B	31.41%
HALO	25.09	162.87	649.21%	0.00%	$ 7.95 B	22.69%
AMGN	25.83	23.00	89.06%	2.61%	$ 199.18 B	20.98%
MCK	26.05	-1,142.11	-4,383.84%	0.33%	$ 113.07 B	1.09%
VRTX	29.34	6.21	21.18%	0.00%	$ 116.00 B	32.94%
CAH	30.92	-19.04	-61.56%	0.94%	$ 51.40 B	0.68%
ADMA	17.56	8.53	48.57%	0.00%	$ 3.68 B	42.87%
BIIB	21.02	1.49	7.08%	0.00%	$ 27.18 B	13.07%
HRMY	10.18	1.86	18.24%	0.00%	$ 1.61 B	18.27%

Stock vs Indice Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

BMRN Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc.

Average Investor10 user rating

4.0 (3 people)

United States

30 years

Founded: 1996

1999

Time since IPO - 27 years

3.059

Employees

The Company BioMarin Pharmaceutical Inc. (United States), is listed on Nasdaq with a market value of $ 11.74 Billions, having an equity of $ 6.09 Billions.

With a total of 3.059 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 3.22 Billions, which generated a loss in the amount of $ 348.91 Millions.

As for its main indicators, the Company has a P/E ratio of 33.63, a P/BV ratio of 1.93 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker BMRN.

Market cap

$ 11.74 Billions

Net worth

$ 6.09 Billions

US$ 6,087,000,000.00

Assets

$ 7.59 Billions

US$ 7,594,020,000.00

Total Shares Outstanding

192.00 Millions

192,000,000

Average Daily Trading Volume

$ 2.20 Millions

US$ 2,196,934.98

Sector

Health Care

Industry

Biotechnology

BMRN

BMRN revenue and profits

Financial Results BMRN

DRAG THE FRAME TO SEE MORE DATA

BMRN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 940.91 45,39% (12M)

P/E

26.05

0.33%

ROE

-4,383.84%

P/BV

-1,142.11

CAH - Cardinal Health

$ 217.08 72,13% (12M)

P/E

30.92

0.94%

ROE

-61.56%

P/BV

-19.04

JNJ - Johnson & Johnson

$ 241.52 52,48% (12M)

P/E

21.49

1.63%

ROE

33.81%

P/BV

7.27

PFE - Pfizer

$ 26.58 10,85% (12M)

P/E

19.79

6.36%

ROE

8.35%

P/BV

1.65

ABBV - AbbVie

$ 219.68 8,02% (12M)

P/E

96.21

2.89%

ROE

0.00%

P/BV

0.00

MRK - Merck & Co.

$ 115.61 27,78% (12M)

P/E

15.74

2.83%

ROE

0.00%

P/BV

0.00

AZN - AstraZeneca

$ 189.90 26,71% (12M)

P/E

29.15

1.63%

ROE

20.99%

P/BV

6.12

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 940.91 45,39% (12 M)

P/L

26.05

0.33%

ROE

-4,383.84%

P/VP

-1,142.11

CAH - Cardinal Health

$ 217.08 72,13% (12 M)

P/L

30.92

0.94%

ROE

-61.56%

P/VP

-19.04

JNJ - Johnson & Johnson

$ 241.52 52,48% (12 M)

P/L

21.49

1.63%

ROE

33.81%

P/VP

7.27

PFE - Pfizer

$ 26.58 10,85% (12 M)

P/L

19.79

6.36%

ROE

8.35%

P/VP

1.65

ABBV - AbbVie

$ 219.68 8,02% (12 M)

P/L

96.21

2.89%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 115.61 27,78% (12 M)

P/L

15.74

2.83%

ROE

0.00%

P/VP

0.00

AZN - AstraZeneca

$ 189.90 26,71% (12 M)

P/L

29.15

1.63%

ROE

20.99%

P/VP

6.12

Frequently Asked Questions

What is the price of BioMarin Pharmaceutical (BMRN) today?

The price of BioMarin Pharmaceutical (BMRN) today is $ 58.51, with return of -17.12% compared to the last year. The price of BioMarin Pharmaceutical (BMRN) started the year trading around $ 59.43 and today it is at $ 58.51. Follow the real-time price chart, the historical price of BioMarin Pharmaceutical (BMRN) and international markets.

When does BioMarin Pharmaceutical (BMRN) pay dividends?

BioMarin Pharmaceutical (BMRN) did not distribute dividends in the last year.

Is BioMarin Pharmaceutical (BMRN) worth it?

Currently, BioMarin Pharmaceutical (BMRN) is priced at $ 58.51, with a P/E of 33.63%, representing a deviation of 7,676% from its historical average P/E. In the last year, the stock showed a variation of -17.12 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was -17.12%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy BioMarin Pharmaceutical (BMRN) stock?

Investing in stocks of BioMarin Pharmaceutical (BMRN) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of BioMarin Pharmaceutical (BMRN) yield today?

The yield of BioMarin Pharmaceutical (BMRN) was -2.98% in the last month, -17.12% in the last year and -25.36% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.

If you wanted to buy 100 stocks of BioMarin Pharmaceutical (BMRN) today, the total investment would be $ 5,851.00, based on the current price of $ 58.51.

If past performance were to repeat, the return on your investment would be:

In 1 year: $ 4,849.31
In 5 years: $ 4,367.19
In 10 years: $ 4,261.28

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

BMRN

BioMarin Pharmaceutical Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment BMRN

review the fundamentals of BioMarin Pharmaceutical shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc.

United States

30 years

1999

3.059

PROFIT X PRICE BMRN

Financial Results BMRN

BMRN cash flow

Asset, Revenue and Profit Growth - BMRN

BMRN balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

Frequently Asked Questions